21/06/2026 MoonLake Immunotherapeutics announced Phase 3 results for sonelokimab in Hidradenitis Suppurativa MoonLake Immunotherapeutics announced Phase 3 results for sonelokimab in Hidradenitis Suppurativa (Ref) MoonLake Immunotherapeutics announced the week 52 results from its Phase 3, VELA-1 and VELA-2 trials of sonelokimab (SLK; IL-17 A/F inhibitor) for the treatment of patients with moderate-to-severe Hidradenitis Suppurativa (HS). At week 52, sonelokimab showed consiste